A Phase 1/2 interventional study of ITF2357 and Placebo in Crohn's Disease, sponsored by Italfarmaco. Terminated at 10 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-07-19.
Sponsored by Italfarmaco · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 194 studies in Crohn Disease with a site in Belgium — 41 open to participants now, 56 under way, 29 of them phase 3. Crohn Disease · Belgium.
Among the 194 studies in Crohn Disease with a site in Belgium, this one is the 146th largest by enrollment of the 175 interventional ones that give a count, is one of 4 that started in 2007, is one of 3 in phase 1/2, and was the 34th registered.
1,993 studies on the registry are indexed under Crohn Disease; 478 are open to participants now.
Browse Crohn Disease studies →41 of the 194 studies in Crohn Disease with a site in Belgium are open now. Recruiting first, the newest first:
Janssen Research & Development, LLC · Sites in Belgium, United States, Argentina and 27 more countries
Ages 18+
Eli Lilly and Company · Sites in Belgium, United States, Brazil and 7 more countries
Ages 18–80
Eli Lilly and Company · Sites in Belgium, United States, Brazil and 7 more countries
Ages 18–80
Imelda GI Clinical Research Center · Sites in Belgium
Ages 16+
Janssen Research & Development, LLC · Sites in Belgium, United States, Austria and 14 more countries
Ages 18+
A study can be open while its sites in Belgium have not opened yet or have stopped. Only those recruiting at a site in Belgium →
Of the 353 Crohn Disease studies recruiting now, 154 (44%) set no upper age limit and 144 (41%) stop at 75 or younger; 95 take children under 18; 56 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
194 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 10 · Phase 2 58 · Phase 3 94 · Phase 4 9
First in 2001; this study’s year is marked. 4 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 51 is below the median of 67 across 1,261 interventional studies indexed under Crohn Disease.
Median enrollment 211 across the 175 interventional studies, 257 across the 19 observational. Of the 135 that completed or were terminated, 83 (61%) have results posted.
This tab as a report to print or save as PDF → With an account.
154 of 194 have an industry lead sponsor. The 10 most frequent:
Italfarmaco is the lead sponsor of 35 studies on the registry; 5 are open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 6 (100%) have results posted.
Italfarmaco has 1 study filed under Crohn Disease — fewer than ten, so there is no comparison to draw.
15 of the studies in Crohn Disease with a site in Belgium that are under way reach primary completion within a year, 7 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05347095Phase 3Janssen-Cilag Ltd.A Study of Guselkumab in Participants With Fistulizing, Perianal Crohn's Disease | 2027-03-25 |
| NCT06408935Phase 3Janssen-Cilag Ltd.Transmural Healing and Disease-Modifying Effect of Guselkumab in Crohn's Disease Patients | 2027-06-08 |
| NCT06227910Phase 3TakedaA Study of Vedolizumab With and Without Upadacitinib in Adults With Crohn's Disease | 2027-06-08 |
| NCT03345823Phase 3AbbVieA Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohn's Disease Who Completed the Studies M14-431 or M14-433 | 2027-09 |
| NCT04779320Phase 3TakedaA Study of Vedolizumab in Children and Teenagers With Moderate to Severe Crohn's Disease (CD) | 2027-09-13 |
Add all 15 to your calendar (.ics) → With an account.
Among the 194 studies in Crohn Disease with a site in Belgium, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Objectives:
The primary objective of the study was to determine the ability of ITF2357, administered orally at the dose of 50 mg b.i.d. for 8 consecutive weeks, to induce complete healing of mucosal ulcerations of ileum and/or colon, assessed by endoscopy, in patients with endoscopic and clinical evidence of active moderate-to-severe Crohn's disease not controlled by conventional therapies.
The secondary objectives of the study were:
The study was conducted according to a randomized, double-blind placebo-controlled, parallel group design in up to 25 clinical sites in Europe.
Eligible patients were randomly assigned to two parallel treatment groups (1:1 randomization ratio) receiving either ITF2357, as hard gelatine capsule for oral administration, at the dose of 50 mg b.i.d. (total daily dose of 100 mg), or matching placebo capsules.
Treatment was administered on an outpatient basis for 8 consecutive weeks, followed by a 4-week follow-up.
During screening, in the 8-week treatment period and in the 4-week follow-up period, patients attended scheduled visits, with physical and laboratory assessments, in order to monitor disease evolution and safety and tolerability of ITF2357.
The study was planned to be conducted in up to 80 patients of both genders, with established diagnosis of CD, who presented with ulcerations greater than aphthous ulcers in at least one of the five bowel segments investigated endoscopically, from the ileum to the rectum, with endoscopic and clinical evidence of moderate-to-severe active disease, not controlled by on-going treatment with conventional therapies such as 5-aminosalicylates, steroids or immunosuppressants.
The present study has been designed in order to assessed wether short-term (8 weeks) treatment with oral ITF2357 can induce disease improvement in a substantial proportion of patients.
Its aim to evaluate whether a short term treatment with ITF2357 for 8 weeks, at the selected dose of 50 mg b.i.d., is able to induce healing of mucosal lesions, evaluated endoscopically, in patients with endoscopic and clinical evidence of moderate-to-severe active Crohn's disease, not controlled by ongoing treatment with conventional therapies such as 5-aminosalicylates, steroids or immunosuppressants, was not addressed and the study was prematurely interrupted according to IDSMC (Independent Data and Safety Monitoring Committee) decision, based on the results of the interim analysis, which did not demonstrate any benefit of ITF2357 over placebo in the primary variable rate of patients achieving complete healing at week 8.
There was also no evidence of benefits in patients treated with ITF2357 compared to placebo in the secondary efficacy endpoints (full remission rate, remission rate, CDEIS endoscopic response, changes from baseline of CDEIS score and SES-CD score, changes from baseline of CDAI score, CDAI remission rate, and CDAI response rate).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Oral matching placebo capsules, administered bid.
Other: Placebo
Oral ITF2357 50 mg bid
Drug: ITF2357
ITF2357 was administered as hard gelatin capsules for oral administration at the dose strength of 50 mg. Capsules were administered as follow: one capsule in the morning and one in the evening.
Also known as: Givinostat
Placebo was supplied as matching capsules for oral administration with the same outer appearance of the study drug and with the same dosing scheme (one capsule in the morning and one in the evening)
Number of Patients Achieving Complete Healing of Mucosal Ulcerations of Ileum and/or Colon
The outcome is assessed by endoscopy, in patients with endoscopic and clinical evidence of active moderate-to-severe Crohn's disease not controlled by conventional therapies. The outcome measure defines the rate of patients achieving complete healing in ITT population, i.e disappearance of mucosal ulceration, obtained with ITF2357 treatment.
Time frame: At week 8
Number of Patients Achieving Full Endoscopic Remission ( Based on CDEIS Score)
CDEIS (Crohn's Disease Endoscopic Index of Severity) is an index for determining the severity of Crohn's disease with endoscopic localization to ileum and colon; A patient was defined 'fully endoscopic remissed' whether the CDEIS score at week 8 was equal or lower than three points CDEIS score considers 4 parameters, each one evaluated in 5 pre-defined segments of the colon. The score can be calculated even in case of incomplete investigations, as the results of the individual segments are divided by the number of segments investigated. Score Scale: \< 3 remission; 3 - 8 mild endoscopic activity; 9 - 12 moderate endoscopic activity; \> 12 severe endoscopic activity. The higher the score, the worse is patient's situation.
Time frame: At Week 8
Number of Patients Achieving Endoscopic Remission (Based on CDEIS Score)
CDEIS (Crohn's Disease Endoscopic Index of Severity) is an index for determining the severity of Crohn's disease with endoscopic localization to ileum and colon; A patient was defined 'endoscopic remissed' whether the CDEIS score at week 8 was equal or lower than six points. CDEIS score considers 4 parameters, each one evaluated in 5 pre-defined segments of the colon ). The score can be calculated even in case of incomplete investigations, as the results of the individual segments are divided by the number of segments investigated. The higher the score, the worse is patient's situation. Score Scale: \< 3 remission; 3 - 8 mild endoscopic activity; 9 - 12 moderate endoscopic activity; \> 12 severe endoscopic activity. A patient was defined 'endoscopic remissed' whether the CDEIS score at week 8 was equal or lower than six points.
Time frame: At week 8
Number of Patients Achieving Endoscopic Response (Based on CDEIS Score)
CDEIS (Crohn's Disease Endoscopic Index of Severity) is an index for determining the severity of Crohn's disease with endoscopic localization to ileum and colon; A patient was considered in 'endoscopic response' whether the change in CDEIS score at week 8 versus baseline was equal or greater than 4.5 points. CDEIS score considers 4 parameters, each one evaluated in 5 pre-defined segments of the colon ). The score can be calculated even in case of incomplete investigations, as the results of the individual segments are divided by the number of segments investigated. The higher the score, the worse is patient's situation Score Scale: \< 3 remission; 3 - 8 mild endoscopic activity; 9 - 12 moderate endoscopic activity; \> 12 severe endoscopic activity. A patient was considered in 'endoscopic response' whether the change in CDEIS score at week 8 versus baseline was equal or greater than 4.5 points.
Time frame: At week 8
The Mean Changes of Crohn's Disease Endoscopic Index of Severity (CDEIS) From Baseline to Week 8
CDEIS is an index to determ the endoscopic severity of Crohn's disease. Its score considers 4 parameters, each one evaluated in 5 pre-defined segments of the colon (ileum, ascending colon, transverse colon, descending colon and sigmoid loop, and rectum). These 4 parameters are: Deep ulcerations (12 if present, 0 if absent = total 1); Superficial ulcerations (6 if present, 0 if absent = total 2); Surface involved by disease (mm/10 on VAS = = total 3); Surface involved by ulcerations (mm/10 on VAS = total 4). Sum of Totals 1+2+3+4 =Total A Number of segments visualized in part or entirely (from 1 to 5)= n Total A/n =Total B if ulcerated stenosis in any segment, add 3 =Total C If non-ulcerated stenosis in any segment, add 3= Total D Total B+C+D=CDEIS grand score (min=0; max=NA) Decoding score \< 3 remission; 3 - 8 mild endoscopic activity; 9 - 12 moderate endoscopic activity; \> 12 severe endoscopic activity. The higher the score, the worse is patient's status.
Time frame: From Baseline to week 8
The Mean Changes of Simple Endoscopic Score for Crohn Disease (SES-CD) From Baseline to Week 8
SES-CD is another index to determ the endoscopic severity of Crohn's disease. Its score considers 4 parameters, each one evaluated in 5 pre-defined segments of the colon (ileum, ascending colon, transverse colon, descending colon and sigmoid loop, and rectum). These 4 parameters are: ulcers? 0: no; 1: aphthous (0.1-0.5 cm); 2: large (0.5-2 cm); 3: very large (\>2 cm); Surface involved by inflammation 0: 0% 1: \<50% 2: 50-75% 3: \>75% Surface involved by ulcerations 0: 0% 1. \<10% 2. 10-30% 3. \>30% Stenosis? 0: No 1. Single, can be passed 2. Multiple, can be passed 3. Cannot be passed The scores for each individual segment are added together as a sum score (min=0; max=60) The higher the score, the worse the outcome. Decoding score 0 - 2 remission 3 - 6 mild endoscopic activity 7 - 15 moderate endoscopic activity \> 15 severe endoscopic activity
Time frame: From Baseline to week 8
The Mean Changes of CDAI Score From Baseline to Week 4-8-follow up
CDAI (Crohn's Disease Activity Index): frequently used to assess disease severity. It gives a score ranging from 0 to over 600, based on a diary of symptoms kept by the patient for 7 days, and other measurements such as the patient's weight and haematocrit. The higher the score, the worse is patient's situation A patient is defined 'remissed' whether the CDAI score is lower than 150 points. A patient is defined 'responder' whether the change in CDAI score versus baseline is greater to 100 points
Time frame: Weeks 4 and 8, and follow-up at 1 month
Number of Patients Achieving Remission (Based on CDAI Score)
"Remission" is defined as the disappearance of signs and symptoms of the disease. CDAI (Crohn's Disease Activity Index): frequently used to assess disease severity. It gives a score ranging from 0 to over 600, based on a diary of symptoms kept by the patient for 7 days, and other measurements such as the patient's weight and haematocrit. The higher the score, the worse is patient's situation A patient is defined 'remissed' whether the CDAI score is lower than 150 points. A patient is defined 'responder' whether the change in CDAI score versus baseline is greater to 100 points
Time frame: Weeks 4 and 8, and follow-up at 1 month
Number of Patients Achieving Response (Based on CDAI Score)
"Response" is defined as the reaction to a stimulus or to a treatment, especially in a favorable way. CDAI (Crohn's Disease Activity Index): frequently used to assess disease severity. It gives a score ranging from 0 to over 600, based on a diary of symptoms kept by the patient for 7 days, and other measurements such as the patient's weight and haematocrit. The higher the score, the worse is patient's situation. A patient is defined 'remissed' whether the CDAI score is lower than 150 points. A patient is defined 'responder' whether the change in CDAI score versus baseline is greater to 100 points
Time frame: Weeks 4 and 8, and follow-up at 1 month
Number of Patients With at Least One Related Adverse Event to Study Treatment
Treatment-related adverse events are adverse events (AE) which occurs during an interventional study and which are surely related to study treatment dosing.
Time frame: At Pre-Treatment period (Week 0); At treatment period (Week 1, Week 2, Week 4, week 6, Week 8); At Follow-up period (1month)
Plasma Levels of ITF2357 Before Morning Dose of ITF2357
Individual plasma levels of ITF2357 (before morning dose) after repeated oral administration of ITF2357 (50mg b.i.d.) in patients with Crohn's disease were assessed.
Time frame: Pre-dose, week 2, week 4, week 6
Plasma Levels of Metabolite ITF2374 Before Morning Dose of ITF2357.
Individual plasma levels of metabolite ITF2374 (before morning dose) after repeated oral administration of ITF2357 (50mg b.i.d.) in patients with Crohn's disease were assessed.
Time frame: Pre-dose, week 2, week 4, week 6
Plasma Levels of Metabolite ITF2375 Before Morning Dose of ITF2357.
Individual plasma levels of Metabolite ITF2375 (before morning dose) after repeated oral administration of ITF2357 (50mg b.i.d.) in patients with Crohn's disease were assessed.
Time frame: Pre dose, week 2, week 4, week 6.
Fifty-one (51) subjects were enrolled in the study, as planned, and 37 of them completed the study as per protocol.
| Milestone | Placebo | ITF2357 |
|---|---|---|
| Started | 26 | 25 |
| Completed | 19 | 18 |
| Not completed | 7 | 7 |
| Withdrew: Disease worsening | 3 | 2 |
| Withdrew: Personal reason | 1 | 0 |
| Withdrew: Adverse event | 1 | 3 |
| Withdrew: Patient's withdrawal of consent | 0 | 1 |
| Withdrew: Termination of the trial by the sponsor | 2 | 0 |
| Withdrew: Other reasons | 0 | 1 |
The outcome is assessed by endoscopy, in patients with endoscopic and clinical evidence of active moderate-to-severe Crohn's disease not controlled by conventional therapies. The outcome measure defines the rate of patients achieving complete healing in ITT population, i.e disappearance of mucosal ulceration, obtained with ITF2357 treatment.
| Participants | Placebo | ITF2357 |
|---|---|---|
| Number of Patients Achieving Complete Healing of Mucosal Ulcerations of Ileum and/or Colon | 0 | 1 |
CDEIS (Crohn's Disease Endoscopic Index of Severity) is an index for determining the severity of Crohn's disease with endoscopic localization to ileum and colon; A patient was defined 'fully endoscopic remissed' whether the CDEIS score at week 8 was equal or lower than three points CDEIS score considers 4 parameters, each one evaluated in 5 pre-defined segments of the colon. The score can be calculated even in case of incomplete investigations, as the results of the individual segments are divided by the number of segments investigated. Score Scale: \< 3 remission; 3 - 8 mild endoscopic activity; 9 - 12 moderate endoscopic activity; \> 12 severe endoscopic activity. The higher the score, the worse is patient's situation.
| Participants | Placebo | ITF2357 |
|---|---|---|
| Number of Patients Achieving Full Endoscopic Remission ( Based on CDEIS Score) | 2 | 1 |
CDEIS (Crohn's Disease Endoscopic Index of Severity) is an index for determining the severity of Crohn's disease with endoscopic localization to ileum and colon; A patient was defined 'endoscopic remissed' whether the CDEIS score at week 8 was equal or lower than six points. CDEIS score considers 4 parameters, each one evaluated in 5 pre-defined segments of the colon ). The score can be calculated even in case of incomplete investigations, as the results of the individual segments are divided by the number of segments investigated. The higher the score, the worse is patient's situation. Score Scale: \< 3 remission; 3 - 8 mild endoscopic activity; 9 - 12 moderate endoscopic activity; \> 12 severe endoscopic activity. A patient was defined 'endoscopic remissed' whether the CDEIS score at week 8 was equal or lower than six points.
| Participants | Placebo | ITF2357 |
|---|---|---|
| Number of Patients Achieving Endoscopic Remission (Based on CDEIS Score) | 3 | 5 |
CDEIS (Crohn's Disease Endoscopic Index of Severity) is an index for determining the severity of Crohn's disease with endoscopic localization to ileum and colon; A patient was considered in 'endoscopic response' whether the change in CDEIS score at week 8 versus baseline was equal or greater than 4.5 points. CDEIS score considers 4 parameters, each one evaluated in 5 pre-defined segments of the colon ). The score can be calculated even in case of incomplete investigations, as the results of the individual segments are divided by the number of segments investigated. The higher the score, the worse is patient's situation Score Scale: \< 3 remission; 3 - 8 mild endoscopic activity; 9 - 12 moderate endoscopic activity; \> 12 severe endoscopic activity. A patient was considered in 'endoscopic response' whether the change in CDEIS score at week 8 versus baseline was equal or greater than 4.5 points.
| Participants | Placebo | ITF2357 |
|---|---|---|
| Number of Patients Achieving Endoscopic Response (Based on CDEIS Score) | 6 | 7 |
CDEIS is an index to determ the endoscopic severity of Crohn's disease. Its score considers 4 parameters, each one evaluated in 5 pre-defined segments of the colon (ileum, ascending colon, transverse colon, descending colon and sigmoid loop, and rectum). These 4 parameters are: Deep ulcerations (12 if present, 0 if absent = total 1); Superficial ulcerations (6 if present, 0 if absent = total 2); Surface involved by disease (mm/10 on VAS = = total 3); Surface involved by ulcerations (mm/10 on VAS = total 4). Sum of Totals 1+2+3+4 =Total A Number of segments visualized in part or entirely (from 1 to 5)= n Total A/n =Total B if ulcerated stenosis in any segment, add 3 =Total C If non-ulcerated stenosis in any segment, add 3= Total D Total B+C+D=CDEIS grand score (min=0; max=NA) Decoding score \< 3 remission; 3 - 8 mild endoscopic activity; 9 - 12 moderate endoscopic activity; \> 12 severe endoscopic activity. The higher the score, the worse is patient's status.
| score on a scale | Placebo | ITF2357 |
|---|---|---|
| The Mean Changes of Crohn's Disease Endoscopic Index of Severity (CDEIS) From Baseline to Week 8 | -2.5 ± 5.6 | -2.4 ± 4.2 |
SES-CD is another index to determ the endoscopic severity of Crohn's disease. Its score considers 4 parameters, each one evaluated in 5 pre-defined segments of the colon (ileum, ascending colon, transverse colon, descending colon and sigmoid loop, and rectum). These 4 parameters are: ulcers? 0: no; 1: aphthous (0.1-0.5 cm); 2: large (0.5-2 cm); 3: very large (\>2 cm); Surface involved by inflammation 0: 0% 1: \<50% 2: 50-75% 3: \>75% Surface involved by ulcerations 0: 0% 1. \<10% 2. 10-30% 3. \>30% Stenosis? 0: No 1. Single, can be passed 2. Multiple, can be passed 3. Cannot be passed The scores for each individual segment are added together as a sum score (min=0; max=60) The higher the score, the worse the outcome. Decoding score 0 - 2 remission 3 - 6 mild endoscopic activity 7 - 15 moderate endoscopic activity \> 15 severe endoscopic activity
| score on a scale | Placebo | ITF2357 |
|---|---|---|
| The Mean Changes of Simple Endoscopic Score for Crohn Disease (SES-CD) From Baseline to Week 8 | -2.6 ± 4.5 | -2.0 ± 4.0 |
CDAI (Crohn's Disease Activity Index): frequently used to assess disease severity. It gives a score ranging from 0 to over 600, based on a diary of symptoms kept by the patient for 7 days, and other measurements such as the patient's weight and haematocrit. The higher the score, the worse is patient's situation A patient is defined 'remissed' whether the CDAI score is lower than 150 points. A patient is defined 'responder' whether the change in CDAI score versus baseline is greater to 100 points
| score on a scale | Placebo | ITF2357 |
|---|---|---|
| At week 4 | -85.3 ± 95.9 | -32.7 ± 84.5 |
| At week 8 | -119 ± 96.5 | -54.7 ± 94.3 |
| At follow-up 1 month | -106 ± 91.6 | -83.8 ± 82.0 |
"Remission" is defined as the disappearance of signs and symptoms of the disease. CDAI (Crohn's Disease Activity Index): frequently used to assess disease severity. It gives a score ranging from 0 to over 600, based on a diary of symptoms kept by the patient for 7 days, and other measurements such as the patient's weight and haematocrit. The higher the score, the worse is patient's situation A patient is defined 'remissed' whether the CDAI score is lower than 150 points. A patient is defined 'responder' whether the change in CDAI score versus baseline is greater to 100 points
| Participants | Placebo | ITF2357 |
|---|---|---|
| At week 4 | 10 | 4 |
| At week 8 | 14 | 7 |
| At follow-up after one month | 11 | 9 |
"Response" is defined as the reaction to a stimulus or to a treatment, especially in a favorable way. CDAI (Crohn's Disease Activity Index): frequently used to assess disease severity. It gives a score ranging from 0 to over 600, based on a diary of symptoms kept by the patient for 7 days, and other measurements such as the patient's weight and haematocrit. The higher the score, the worse is patient's situation. A patient is defined 'remissed' whether the CDAI score is lower than 150 points. A patient is defined 'responder' whether the change in CDAI score versus baseline is greater to 100 points
| Participants | Placebo | ITF2357 |
|---|---|---|
| At week 4 | 11 | 6 |
| At week 8 | 14 | 8 |
| At follow up, after one month | 14 | 11 |
Treatment-related adverse events are adverse events (AE) which occurs during an interventional study and which are surely related to study treatment dosing.
| Participants | Placebo | ITF2357 |
|---|---|---|
| Number of Patients With at Least One Related Adverse Event to Study Treatment | 13 | 12 |
Individual plasma levels of ITF2357 (before morning dose) after repeated oral administration of ITF2357 (50mg b.i.d.) in patients with Crohn's disease were assessed.
| ng/mL | ITF2357 |
|---|---|
| Pre-dose | 0.00 ± 0.00 |
| Week 2 | 16.87 ± 6.09 |
| Week 4 | 16.97 ± 11.54 |
| Week 6 | 14.50 ± 6.78 |
Individual plasma levels of metabolite ITF2374 (before morning dose) after repeated oral administration of ITF2357 (50mg b.i.d.) in patients with Crohn's disease were assessed.
| ng/mL | ITF2357 |
|---|---|
| Pre-dose | 0.00 ± 0.00 |
| Week 2 | 15.09 ± 6.92 |
| Week 4 | 12.93 ± 7.36 |
| Week 6 | 13.24 ± 8.16 |
Individual plasma levels of Metabolite ITF2375 (before morning dose) after repeated oral administration of ITF2357 (50mg b.i.d.) in patients with Crohn's disease were assessed.
| ng/mL | ITF2357 |
|---|---|
| pre-dose | 0.00 ± 0.00 |
| week 2 | 121.23 ± 88.83 |
| week 4 | 112.80 ± 109.74 |
| week 6 | 101.36 ± 76.32 |
Collected over Adverse event data were collected from Week 0 up to week 8 and during follow up period (which lasts for one month). Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 0/26 (0%) | 2/26 (7.7%) | 17/26 (65.4%) |
| ITF2357 | 0/25 (0%) | 3/25 (12%) | 20/25 (80%) |
| Event | Placebo | ITF2357 |
|---|---|---|
| Crohn's DiseaseGastrointestinal disorders | 1/26 | 3/25 |
| Back PainMusculoskeletal and connective tissue disorders | 1/26 | 0/25 |
| Event | Placebo | ITF2357 |
|---|---|---|
| VomitingGastrointestinal disorders | 1/26 | 6/25 |
| Abdominal painGastrointestinal disorders | 4/26 | 5/25 |
| Crohn's diseaseGastrointestinal disorders | 3/26 | 4/25 |
| Abdominal pain upperGastrointestinal disorders | 1/26 | 3/25 |
| DyspepsiaGastrointestinal disorders | 0/26 | 3/25 |
| NauseaGastrointestinal disorders | 1/26 | 3/25 |
| PyrexiaGeneral disorders | 0/26 | 3/25 |
| DehydrationMetabolism and nutrition disorders | 0/26 | 3/25 |
| HypokalaemiaMetabolism and nutrition disorders | 0/26 | 3/25 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 2/26 | 3/25 |
ITT: All randomized patients who received at least one treatment with study medication
| Age, Categorical(Participants) | Placebo | ITF2357 | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 26 | 24 | 50 |
| >=65 years | 0 | 1 | 1 |
| Sex: Female, Male(Participants) | Placebo | ITF2357 | Total |
|---|---|---|---|
| Female | 16 | 14 | 30 |
| Male | 10 | 11 | 21 |
| Race (NIH/OMB)(Participants) | Placebo | ITF2357 | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 26 | 25 | 51 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
Ran from Oct 2007 to primary completion in Dec 2008, 14 months.
Results were first posted in Jul 2023, 14 years 7 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Jan 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Givinostat